Vascular and Alzheimer's disease markers independently predict brain atrophy rate in Alzheimer's Disease Neuroimaging Initiative controls

Neurobiology of Aging

Volumn 34, Issue 8, 2013, Pages 1996-2002

  Barnes, Josephine ^a   Carmichael, Owen T ^b   Leung, Kelvin K ^a   Schwarz, Christopher ^b   Ridgway, Gerard R ^c   Bartlett, Jonathan W ^d   Malone, Ian B ^a   Schott, Jonathan M ^a   Rossor, Martin N ^a   Biessels, Geert Jan ^e   DeCarli, Charlie ^b   Fox, Nick C ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c WELLCOME TRUST CENTRE FOR NEUROIMAGING   (United Kingdom)

^d LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^e UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Alzheimer's disease; Mild cognitive impairment (MCI); Normal aging; Vascular disease; Volumetric MRI

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; TAU PROTEIN;

AGED; ALZHEIMER DISEASE; ARTICLE; BLOOD VESSEL INJURY; BRAIN ATROPHY; BRAIN SIZE; CEREBROSPINAL FLUID ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; NEUROIMAGING; NEUROPATHOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PSYCHOLOGIC ASSESSMENT; VASCULAR DISEASE; WHITE MATTER;

AGED; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ATROPHY; BIOLOGICAL MARKERS; BRAIN; CEREBRAL ARTERIES; DISEASE PROGRESSION; FEMALE; FUNCTIONAL NEUROIMAGING; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MILD COGNITIVE IMPAIRMENT; PEPTIDE FRAGMENTS; TAU PROTEINS;

EID: 84877593391     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2013.02.003     Document Type: Article

References (49)

1. Brayne C., Richardson K., Matthews F.E., Fleming J., Hunter S., Xuereb J.H., Paykel E., Mukaetova-Ladinska E.B., Huppert F.A., O'Sullivan A., Dening T. Neuropathological correlates of dementia in over-80-year-old brain donors from the population-based Cambridge city over-75s cohort (CC75C) study. J. Alzheimers Dis. 2009, 18:645-658.
2. Carmichael O., Mungas D., Beckett L., Harvey D., Tomaszewski F.S., Reed B., Olichney J., Miller J., DeCarli C. MRI predictors of cognitive change in a diverse and carefully characterized elderly population. Neurobiol. Aging 2012, 33:83-95.
3. Carmichael O., Schwarz C., Drucker D., Fletcher E., Harvey D., Beckett L., Jack C.R., Weiner M., DeCarli C. Longitudinal changes in white matter disease and cognition in the first year of the Alzheimer disease neuroimaging initiative. Arch. Neurol. 2010, 67:1370-1378.
4. Debette S., Seshadri S., Beiser A., Au R., Himali J.J., Palumbo C., Wolf P.A., DeCarli C. Midlife vascular risk factor exposure accelerates structural brain aging and cognitive decline. Neurology 2011, 77:461-468.
5. DeCarli C., Massaro J., Harvey D., Hald J., Tullberg M., Au R., Beiser A., D'Agostino R., Wolf P.A. Measures of brain morphology and infarction in the framingham heart study: establishing what is normal. Neurobiol. Aging 2005, 26:491-510.
6. DeCarli C., Miller B.L., Swan G.E., Reed T., Wolf P.A., Carmelli D. Cerebrovascular and brain morphologic correlates of mild cognitive impairment in the National Heart, Lung, and Blood Institute Twin Study. Arch. Neurol. 2001, 58:643-647.
7. Evans M.C., Barnes J., Nielsen C., Kim L.G., Clegg S.L., Blair M., Leung K.K., Douiri A., Boyes R.G., Ourselin S., Fox N.C. Volume changes in Alzheimer's disease and mild cognitive impairment: cognitive associations. Eur. Radiol. 2010, 20:674-682.
8. Fjell A.M., Walhovd K.B., Fennema-Notestine C., McEvoy L.K., Hagler D.J., Holland D., Brewer J.B., Dale A.M. CSF biomarkers in prediction of cerebral and clinical change in mild cognitive impairment and Alzheimer's disease. J. Neurosci. 2010, 30:2088-2101.
9. Freeborough P.A., Fox N.C. The boundary shift integral: an accurate and robust measure of cerebral volume changes from registered repeat MRI. IEEE. Trans. Med. Imaging 1997, 16:623-629.
10. Freeborough P.A., Fox N.C., Kitney R.I. Interactive algorithms for the segmentation and quantitation of 3-D MRI brain scans. Comput Methods Programs Biomed. 1997, 53:15-25.
11. Godin O., Maillard P., Crivello F., Alperovitch A., Mazoyer B., Tzourio C., Dufouil C. Association of white-matter lesions with brain atrophy markers: the three-city Dijon MRI study. Cerebrovasc. Dis. 2009, 28:177-184.
12. Gorelick P.B., Scuteri A., Black S.E., DeCarli C., Greenberg S.M., Iadecola C., Launer L.J., Laurent S., Lopez O.L., Nyenhuis D., Petersen R.C., Schneider J.A., Tzourio C., Arnett D.K., Bennett D.A., Chui H.C., Higashida R.T., Lindquist R., Nilsson P.M., Roman G.C., Sellke F.W., Seshadri S. Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2011, 42:2672-2713.
13. Gouw A.A., Seewann A., van der Flier W.M., Barkhof F., Rozemuller A.M., Scheltens P., Geurts J.J. Heterogeneity of small vessel disease: a systematic review of MRI and histopathology correlations. J. Neurol. Neurosurg. Psychiatry 2011, 82:126-135.
14. Gurol M.E., Irizarry M.C., Smith E.E., Raju S., Diaz-Arrastia R., Bottiglieri T., Rosand J., Growdon J.H., Greenberg S.M. Plasma beta-amyloid and white matter lesions in AD, MCI, and cerebral amyloid angiopathy. Neurology 2006, 66:23-29.
15. Henneman W.J., Sluimer J.D., Barnes J., van der Flier W.M., Sluimer I.C., Fox N.C., Scheltens P., Vrenken H., Barkhof F. Hippocampal atrophy rates in Alzheimer disease: added value over whole brain volume measures. Neurology 2009, 72:999-1007.
16. Jack C.R., Knopman D.S., Jagust W.J., Shaw L.M., Aisen P.S., Weiner M.W., Petersen R.C., Trojanowski J.Q. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol. 2010, 9:119-128.
17. Jack C.R.J., Shiung M.M., Gunter J.L., O'Brien P.C., Weigand S.D., Knopman D.S., Boeve B.F., Ivnik R.J., Smith G.E., Cha R.H., Tangalos E.G., Petersen R.C. Comparison of different MRI brain atrophy rate measures with clinical disease progression in AD. Neurology 2004, 62:591-600.
18. Jeerakathil T., Wolf P.A., Beiser A., Massaro J., Seshadri S., D'Agostino R.B., DeCarli C. Stroke risk profile predicts white matter hyperintensity volume: the Framingham Study. Stroke 2004, 35:1857-1861.
19. Jellinger K.A. Clinicopathological analysis of dementia disorders in the elderly-an update. J. Alzheimers. Dis. 2006, 9:61-70.
20. Jicha G.A., Parisi J.E., Dickson D.W., Johnson K., Cha R., Ivnik R.J., Tangalos E.G., Boeve B.F., Knopman D.S., Braak H., Petersen R.C. Neuropathologic outcome of mild cognitive impairment following progression to clinical dementia. Arch. Neurol. 2006, 63:674-681.
21. Josephs K.A., Whitwell J.L., Ahmed Z., Shiung M.M., Weigand S.D., Knopman D.S., Boeve B.F., Parisi J.E., Petersen R.C., Dickson D.W., Jack C.R. Beta-amyloid burden is not associated with rates of brain atrophy. Ann. Neurol. 2008, 63:204-212.
22. Kim K.W., MacFall J.R., Payne M.E. Classification of white matter lesions on magnetic resonance imaging in elderly persons. Biol. Psychiatry 2008, 64:273-280.
23. Le Bastard N., Leurs J., Blomme W., De Deyn P.P., Engelborghs S. Plasma amyloid-beta forms in Alzheimer's disease and non-Alzheimer's disease patients. J. Alzheimers. Dis. 2010, 21:291-301.
24. Leow A.D., Yanovsky I., Parikshak N., Hua X., Lee S., Toga A.W., Jack C.R., Bernstein M.A., Britson P.J., Gunter J.L., Ward C.P., Borowski B., Shaw L.M., Trojanowski J.Q., Fleisher A.S., Harvey D., Kornak J., Schuff N., Alexander G.E., Weiner M.W., Thompson P.M. Alzheimer's disease neuroimaging initiative: a one-year follow up study using tensor-based morphometry correlating degenerative rates, biomarkers and cognition. Neuroimage 2009, 45:645-655.
25. Leung K.K., Barnes J., Modat M., Ridgway G.R., Bartlett J.W., Fox N.C., Ourselin S. Brain MAPS: an automated, accurate and robust brain extraction technique using a template library. Neuroimage 2011, 55:1091-1108.
26. Leung K.K., Barnes J., Ridgway G.R., Bartlett J.W., Clarkson M.J., Macdonald K., Schuff N., Fox N.C., Ourselin S. Automated cross-sectional and longitudinal hippocampal volume measurement in mild cognitive impairment and Alzheimer's disease. Neuroimage 2010, 51:1345-1359.
27. Leung K.K., Clarkson M.J., Bartlett J.W., Clegg S., Jack C.R., Weiner M.W., Fox N.C., Ourselin S. Robust atrophy rate measurement in Alzheimer's disease using multi-site serial MRI: tissue-specific intensity normalization and parameter selection. Neuroimage 2010, 50:516-523.
28. Mullard A. Sting of Alzheimer's failures offset by upcoming prevention trials. Nat. Rev. Drug Discov. 2012, 11:657-660.
29. Nordahl C.W., Ranganath C., Yonelinas A.P., DeCarli C., Fletcher E., Jagust W.J. White matter changes compromise prefrontal cortex function in healthy elderly individuals. J. Cogn. Neurosci. 2006, 18:418-429.
30. Petersen R.C., Parisi J.E., Dickson D.W., Johnson K.A., Knopman D.S., Boeve B.F., Jicha G.A., Ivnik R.J., Smith G.E., Tangalos E.G., Braak H., Kokmen E. Neuropathologic features of amnestic mild cognitive impairment. Arch. Neurol. 2006, 63:665-672.
31. Reiman E.M., Langbaum J.B., Tariot P.N. Alzheimer's prevention initiative: a proposal to evaluate presymptomatic treatments as quickly as possible. Biomark. Med. 2010, 4:3-14.
32. Richard E., Andrieu S., Solomon A., Mangialasche F., Ahtiluoto S., Moll van Charante E.P., Coley N., Fratiglioni L., Neely A.S., Vellas B., van Gool W.A., Kivipelto M. Methodological challenges in designing dementia prevention trials-the European Dementia Prevention Initiative (EDPI). J. Neurol. Sci. 2012, 322:64-70.
33. Ridgway G., Barnes J., Pepple T., Fox N. Estimation of total intracranial volume: a comparison of methods. Alzheimers Dement. 2011, 7:S62-S63.
34. Schneider J.A., Arvanitakis Z., Bang W., Bennett D.A. Mixed brain pathologies account for most dementia cases in community-dwelling older persons. Neurology 2007, 69:2197-2204.
35. Schott J.M., Bartlett J.W., Barnes J., Leung K.K., Ourselin S., Fox N.C. Reduced sample sizes for atrophy outcomes in Alzheimer's disease trials: baseline adjustment. Neurobiol. Aging 2010, 31:1452-1462. 1462.
36. Schott J.M., Bartlett J.W., Fox N.C., Barnes J. Increased brain atrophy rates in cognitively normal older adults with low cerebrospinal fluid Abeta1-42. Ann. Neurol. 2010, 68:825-834.
37. Schott J.M., Price S.L., Frost C., Whitwell J.L., Rossor M.N., Fox N.C. Measuring atrophy in Alzheimer disease-A serial MRI study over 6 and 12 months. Neurology 2005, 65:119-124.
38. Schuff N., Woerner N., Boreta L., Kornfield T., Shaw L.M., Trojanowski J.Q., Thompson P.M., Jack C.R., Weiner M.W. MRI of hippocampal volume loss in early Alzheimer's disease in relation to ApoE genotype and biomarkers. Brain 2009, 132:1067-1077.
39. Schwarz C., Fletcher E., DeCarli C., Carmichael O. Fully-automated white matter hyperintensity detection with anatomical prior knowledge and without FLAIR. Inf. Process Med. Imaging 2009, 21:239-251.
40. Selkoe D.J. Preventing Alzheimer's disease. Science 2012, 337:1488-1492.
41. Shaw L.M., Vanderstichele H., Knapik-Czajka M., Clark C.M., Aisen P.S., Petersen R.C., Blennow K., Soares H., Simon A., Lewczuk P., Dean R., Siemers E., Potter W., Lee V.M., Trojanowski J.Q. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann. Neurology 2009, 65:403-413.
42. Silbert L.C., Nelson C., Howieson D.B., Moore M.M., Kaye J.A. Impact of white matter hyperintensity volume progression on rate of cognitive and motor decline. Neurology 2008, 71:108-113.
43. Sluimer J.D., Bouwman F.H., Vrenken H., Blankenstein M.A., Barkhof F., van der Flier W.M., Scheltens P. Whole-brain atrophy rate and CSF biomarker levels in MCI and AD: a longitudinal study. Neurobiol. Aging 2010, 31:758-764.
44. Tiehuis A.M., Vincken K.L., Mali W.P., Kappelle L.J., Anbeek P., Algra A., Biessels G.J. Automated and visual scoring methods of cerebral white matter hyperintensities: relation with age and cognitive function. Cerebrovasc. Dis. 2008, 25:59-66.
45. Tosun D., Schuff N., Truran-Sacrey D., Shaw L.M., Trojanowski J.Q., Aisen P., Peterson R., Weiner M.W. Relations between brain tissue loss, CSF biomarkers, and the ApoE genetic profile: a longitudinal MRI study. Neurobiol. Aging 2010, 31:1340-1354.
46. Wen W., Sachdev P.S., Chen X., Anstey K. Gray matter reduction is correlated with white matter hyperintensity volume: a voxel-based morphometric study in a large epidemiological sample. Neuroimage 2006, 29:1031-1039.
47. White L., Petrovitch H., Hardman J., Nelson J., Davis D.G., Ross G.W., Masaki K., Launer L., Markesbery W.R. Cerebrovascular pathology and dementia in autopsied Honolulu-Asia Aging Study participants. Ann. N.Y. Acad. Sci. 2002, 977:9-23.
48. Wilson R.S., Leurgans S.E., Boyle P.A., Schneider J.A., Bennett D.A. Neurodegenerative basis of age-related cognitive decline. Neurology 2010, 75:1070-1078.
49. Yoshita M., Fletcher E., Harvey D., Ortega M., Martinez O., Mungas D.M., Reed B.R., DeCarli C.S. Extent and distribution of white matter hyperintensities in normal aging, MCI, and AD. Neurology 2006, 67:2192-2198.